Scientific Industries (SCND) Registration Filing summary

Company overview and business model

• Designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems for research use in universities, pharma, and industry.

• Operates two segments: legacy benchtop equipment (mixers, shakers, scales, pill counters) and bioprocessing systems (smart sensors, analytics, software).

• Bioprocessing operations are primarily based in Germany, with a focus on growth in the synthetic biology market.

• Major product, Vortex-Genie 2 Mixer, accounts for a significant portion of segment revenue.

Financial performance and metrics

• Net loss of $1.78M for Q1 2025, $6.45M for 2024, and $9.09M for 2023; accumulated deficit of $35.7M as of March 31, 2025.

• Q1 2025 net revenues decreased 3.1% to $2.41M; 2024 net revenues decreased 3.6% to $10.71M.

• Gross profit margin was 42.2% for Q1 2025 and 44.2% for 2024, down from 45.9% in 2023.

• Negative cash flow from operations: $1.33M for Q1 2025, $3.68M for 2024; cash and equivalents at $587,900 as of Dec 31, 2024.

• No income tax expense due to full valuation allowance on deferred tax assets.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; proceeds from warrant exercises will be used for working capital.

• Company intends to retain future earnings for business development and does not expect to pay dividends.